Navigation Links
What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells?
Date:2/17/2009

PPAR- gamma is manifested in a variety of tissues and cancer cells and the ligands that activate PPAR- PPAR- are currently being studied as a novel treatment. The PPAR-gamma ligand generally decreases the survival rate of cancer cells via differentiation, apoptotic induction, and changes in genes or proteins associated with entrance into the G1/S phase. There have been some reports suggesting that stomach cancer cells manifest PPAR- gamma and are suppressed by the PPAR- gamma ligand. Recently, another report has shown that troglitazone, the ligand of PPAR- gamma , may prove useful in preventive medicine, and this effect is dependent on PPAR- gamma .

A research article to be published in volume 15 on January 21, 2009 in the World Journal of Gastroenterology addresses this point. A research team led by Professor DH Kim from the Medical Research Institute, Pusan National University Hospital, Korea found that the reaction of the PPAR- gamma agonist pathway on PPAR- gamma , troglitazone, suppresses the proliferation of colon cancer cells, and induces apoptosis, and expression of the growth response-1 gene in early phase. These processes are activated downstream of the suppression one by one via a PPAR- gamma -independent pathway. Moreover, an inductive chemical compound associated with CDDO causes PPAR- gamma -dependent caveolin expression and a PPAR- gamma -independent induction of the apoptosis reaction.

This report shows that ciglitazone and troglitazone suppress the proliferation of stomach cancer cells via the arrest of G1 phase. The arrest of G1 phase was reported in colon cancer cells via activation of PPAR- gamma. Also, each of the stomach cancer cell types which demonstrated p53 mutations were suppressed more strongly by troglitazone than by ciglitazone, and this effect was more evident in the SNU-668 than in the SNU-216 cells. SNU-668 cells demonstrated p53 and ras mutations, and it will be necessary in future studies to clarify the relationship between these results and the underlying mechanisms. This means that the concentrations of troglitazone that are used clinically suppress the growth of stomach cancer cells, and this may be used as a method to target therapy of gastric cancer.


'/>"/>

Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Escape cancer, but age sooner? The dark side of the tumor suppressing process
2. USC researchers identify novel approach for suppressing prostate cancer development
3. Cancer-Suppressing Gene Tied to Female Fertility
4. Study shows suppressing herpes virus may reduce infectiousness of HIV
5. MU researcher demonstrates non-traditional therapy is effective as pain management
6. Absolutely PR's Maggie Holben Participates In CBSA BioBreakfast Expert Panel "How to Garner Media Attention & Effectively Use Public Relations Tactics"
7. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
8. Drug Rehab Mountainside Treatment Center is an Effective and Quality Option for Those Seeking Drug Treatment - Located Close to NY MA
9. The Effects of Probiotics on the Aging Digestive Tract to be Presented at Nutracon 2009
10. Potential atherosclerosis drug exhibits no harmful side-effects in liver
11. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... , ... “Letters From Home”: a moving compilation of letters that remind ... “Letters From Home” is the creation of published author, John Allred, a passionate leader ... Savelle Ministries International, who has traveled and ministered on four continents. , “It is ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... other tick-borne diseases through research, education and awareness, today announced the appointment of ... immunologist and microbiologist, Dr. Sellati has more than 20 years of research experience ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices ... – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in ... afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring at ...
(Date:9/21/2017)... Church, VA (PRWEB) , ... September 21, 2017 ... ... Policy , **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive ... edge they can get while staying in compliance with FDA rules. , The ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Bill Howe ... to its customers, and give back to the community. For over 37 years, they ... most successful companies serving plumbing in San Diego. They were chosen as ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
Breaking Medicine Technology: